A Common Polymorphism in the Complement Factor H Gene Is Associated With Increased Risk of Myocardial Infarction
The Rotterdam Study
Isabella Kardys, MD*,
Caroline C.W. Klaver, MD, PhD*, ,
Dominiek D.G. Despriet, MD*, ,
Arthur A.B. Bergen, PhD¶,||,
André G. Uitterlinden, PhD ,
Albert Hofman, MD, PhD*,
Ben A. Oostra, PhD ,
Cornelia M. Van Duijn, PhD*,
Paulus T.V.M. de Jong, MD, PhD*,¶,# and
Jacqueline C.M. Witteman, PhD*,*
* Epidemiology & Biostatistics
Ophthalmology
Internal Medicine
Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands
¶ Department of Ophthalmogenetics, Netherlands Ophthalmic Research Institute, Royal Netherlands Academy of Arts and Sciences, Amsterdam, the Netherlands
|| Clinical Genetics
# Ophthalmology, Academic Medical Center, Amsterdam, the Netherlands

View larger version (14K):
[in a new window]
|
Figure 1 Flow chart describing study population. CFH = complement inhibitor factor H; DNA = deoxyribonucleic acid.
|
|

View larger version (18K):
[in a new window]
|
Figure 2 Age- and gender-adjusted event-free survival until incident myocardial infarction.
|
|

View larger version (27K):
[in a new window]
|
Figure 3 Age- and gender-adjusted hazard ratios for myocardial infarction according to Tyr402His genotype in subgroups, created according to median values for continuous variables. BMI = body mass index; CRP = C-reactive protein; HDL = high-density lipoprotein.
|
|
|